We sort of knew to expect great results from the CAPRA study. Lets hope the market rewards the company's efforts with another strong rise in shareprice tomorrow.
There does appear that response rates are markedly better when Cavatak is delivered via direct injecton (intratumorally or intralesionally) as opposed to intravenously. So, lets hope that the data to come out of the STORM trial is viewed in context with what other combination drug trials have produced. It would be a shame for the market to make a comparison to Cavatak's other combo trials... when the various cancers are being treated intravenously in this trial.
Bring on the presentations and results from the MITCI and STORM trials. Its been a long wait. And we here in Aus won't get news til late evening.
Abstract CT114 withheld due to inclusion in official press program, page-42
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)